| ￥3500 | |
| Z04845-100 | |
|
|
|
|
|
|
|
|
|
| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 14.25 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 20-25 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized IL-5, His, Cynomolgus, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Human IL-5 R alpha, hFc Tag with the EC50 of 18.9ng/ml determined by ELISA. »
The purity of IL-5, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
IL-5, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | IL-5 is an important cytokine for priming and survival of mature eosinophils and for proliferation and maturation of their progenitors. IL-5(Rα) targeting will be increasingly used in diseases where eosinophils are the key immune effector cells such as eosinophilic asthma (EA), hypereosinophilic syndrome (HES), eosinophilic esophagitis (EE), and eosinophilic granulomatosis with polyangiitis (EGPA). |
| Synonyms | Interleukin-5; IL-5; T-cell replacing factor; TRF; EDF |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
